Close

Analyst Ratings for PhaseBio Pharmaceuticals Inc. (PHAS)

PHAS Rating Summary

  |   Expand Research on PHAS
Overall Rating: NEUTRAL   Rating Trend: =   Avg. $ Target: N/A
Rating Score: 3.3 / 10   Percentile Rank: 30%
Date Firm Analyst Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
10/24/2022 TD Cowen Phil Nadeau Downgrade Hold
(Buy)
N/A
(N/A)
0.20
(0.07)
-65% Details
9/28/2022 Stifel Annabel Samimy Downgrade Hold
(Buy)
1.00
(N/A)
0.76
(0.07)
-90.79% Details